Blacksmith announces merger with Forge Therapeutics

To create leading company developing medicines targeting metalloenzymes

Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Evonik invests in US based biopharma company ‘Allay Therapeutics’

Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer

Inceptua Early Access and Sentynl Therapeutics launch early access program for Nulibry for pediatric patients

MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae

Pfizer acquires Global Blood Therapeutics

Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.

ProBioGen enters into master service agreement with NextPoint Therapeutics

The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.

Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology

Collaboration supports multiple discovery efforts, including vaccines

Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia